![CONTACT-03: underscoring the need to identify new treatment strategies in metastatic renal cancer after disease progression with prior immunotherapy - VHIO CONTACT-03: underscoring the need to identify new treatment strategies in metastatic renal cancer after disease progression with prior immunotherapy - VHIO](https://vhio.net/wp-content/uploads/2023/07/Banner-web-VHIO-1300-%C3%97-600-px-3-256x256.jpg)
CONTACT-03: underscoring the need to identify new treatment strategies in metastatic renal cancer after disease progression with prior immunotherapy - VHIO
![CONTACT-03: underscoring the need to identify new treatment strategies in metastatic renal cancer after disease progression with prior immunotherapy - VHIO CONTACT-03: underscoring the need to identify new treatment strategies in metastatic renal cancer after disease progression with prior immunotherapy - VHIO](https://vhio.net/wp-content/uploads/2023/02/cristina-saurez-web-3-thegem-blog-default.jpg)
CONTACT-03: underscoring the need to identify new treatment strategies in metastatic renal cancer after disease progression with prior immunotherapy - VHIO
![Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial | AIOM Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial | AIOM](https://sp-ao.shortpixel.ai/client/to_webp,q_glossy,ret_img,w_223,h_300/https://www.aiom.it/wp-content/uploads/2020/07/TheLancet-223x300.png)
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial | AIOM
![Neeraj Agarwal, MD, FASCO on Twitter: "@Montypal never tires of highlighting and praising others' work but rarely talks about his own accomplishments👉 THREE back-to-back FIRST author @TheLancet papers on original research in Neeraj Agarwal, MD, FASCO on Twitter: "@Montypal never tires of highlighting and praising others' work but rarely talks about his own accomplishments👉 THREE back-to-back FIRST author @TheLancet papers on original research in](https://pbs.twimg.com/media/Fx51aL4agAIVOOV.jpg:large)
Neeraj Agarwal, MD, FASCO on Twitter: "@Montypal never tires of highlighting and praising others' work but rarely talks about his own accomplishments👉 THREE back-to-back FIRST author @TheLancet papers on original research in
![Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial - The Lancet Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial - The Lancet](https://www.thelancet.com/cms/asset/073b4386-a995-486e-9cc5-f9da92e896f1/gr1.jpg)